Yunding Xinyao completed a $310 million round C financing

, announced the completion of a $310m round of C financing. The current round of $310 million includes two preferred stock financings, $260 million for rounds C-2 and $50 million for rounds C-1. The C-2 roundled by Janchor Partners, RA Capital Management and Hillhouse Capital. Additional support has been provided by other new investors, including Decheng Capital, GT Fund, Janus Henderson Investors, Rock Springs Capital, Octagon Investments and a large, well-known long-term institutional investor. Existing investors including CBC Group, Cormorant, Pavilion Capital and HBM Healthcare Investments are also actively involved in the round. The C-1 round of financing, which includes a $50 million investment from Jiashan Guo Investment, is part of a broad strategic partnership announced by Yunding Xinyao on March 17, 2020 with Jiashan National Economic and Technological Development Zone and Jiashan Guo Investment.This round of financing will be used to advance the clinical development of The New Yao Innovative Pharmaceutical Products Pipeline at Yunding and to build a strong commercial infrastructure for the next phase of growth.Yikai Capital acted as an exclusive financial advisor to Yunding Xinyao in this transaction.Several pipelines have been launched in China for post-clinical trialsYunding Xinyao is a biopharmaceutical company focused on innovative drug development and commercialization, dedicated to meeting unseeled medical needs in China and other Asian markets. Its product pipeline covers four major areas: tumor, immunological disease, infectious disease and cardionephrosis disease, all of which have great clinical unseeded needs and market potential in the Asia-Pacific region. Each of the pipeline's products has billions of yuan in sales potential in the Chinese market alone.Led by Kangqiao Capital, Yunding Xinyao brings together the world's top talent in product BD, clinical registration and development, product commercialization, capital operation, and more. The management team has deep expertise and experience in high-quality clinical development, pharmaceutical affairs, chemical manufacturing and control (CMC), business development and operations at home and abroad. Less than 3 years after its establishment, the company's achievements in clinical progress and commercialization of its product pipelines, as well as its popularity in global capital markets, are evidence of the strong execution and deep industry understanding of its team.To date, Yunding Xinyao has established eight potentially world-first or best-in-class molecular combinations, many of which are in the late stages of clinical development and cover therapeutic areas such as oncology, autoimmune diseases, cardionephromic diseases and infectious diseases. Four drugs are currently in clinical trials in China, and two more will be registered in 2020.Trocituzumab govitecan-hziy, a similar first anti-Trap-2 antibody drug coupled (ADC), has been approved in the United States for the treatment of metastasis triple negative breast cancer (mTNBC) patients who have received at least two treatments in the past. Yunding Xinyao obtained approval for the Chinese clinical trial of sacituzumab govitecan in April 2020 and plans to launch clinical research and development projects for multiple solid tumor adaptations.XeravaTM (Eravacycline) iracycline is a new, fully synthetic broad-spectrum tetrahedrin non-intestinal antibiotic injected with a wide range of in-body antibacterial activity against drug-resistant bacteria commonly found in China, such as multi-drug resistant Terranean-negative bacteria. Ira cyclocin is currently approved in the United States and Europe for the treatment of patients with complex celiac infection (cIAI), which was approved by Singapore in April 2020. Yunding Xinyao is currently conducting Phase III clinical trials of the allergy in China to support regulatory approval.Etrasimod is a potentially best-in-class oral S1P subject regulator. Yunding Xinyao is conducting multi-center Phase III clinical trials of ulcerative colitis in China and South Korea.Taniborbactam is a potentially best-in-class injection ring borate compound that inhibits both serine and β-endamidease. Yunding Xinyao and its partner Ventorx Pharmaceuticals are currently conducting a global Phase III clinical trial for patients with complex urinary tract infections (cUTI).Ralinepag XR is a potentially best-in-class oral IP-subjected re-release exciter, primarily used to treat patients with pulmonary hypertension (PAH). Yunding Xinyao is working with its partner United Therapeutics on a global Phase III clinical trial for patients with pulmonary hypertension.Nefecon is a potentially world-first innovative product for IGA kidney disease. In December 2019, Yunding Xinyao obtained approval for a clinical trial for IgA kidney disease. Yunding Xinyao will conduct a Global Phase III clinical trial in partnership with its partner Caliditas Therapeutics.FGF401 is a potentially similar first-of-its-kind FGFR4 inhibitor with ATP competitive and reversible co-price. Yunding Xinyao has acquired global commercial rights to the drug from Novaral. In March 2020, a clinical trial application for phase IB/II clinical trials in patients with hepatocellular carcinoma in China was approved.SPR206 is a potentially best-in-class derivative of polyciscosin to reduce the clinically visible toxicity of polyciscosin B and viscose to the kidneys.Kerry Blanchard, M.D., CEO and Chief Executive Officer of Yunding Xinyao, said, "This is an important milestone for Yunding Xinyao, strengthening our deep industry expertise and strategic business model to empower the introduction of global innovative therapies and to develop them in Greater China and Asia. We are ready to advance clinical research into our powerful product pipelines, which cover many important diseases, and look forward to growing our commercial business on this basis. "" Yunding Xinyao has achieved remarkable results, with the industry's well-known enterprises to establish a strategic partnership to build a promising product pipeline," said He Zhi'an, founder and chief industrial investor of Jian . "We are excited to work with Yunding Xinyao and support the company's mission to provide innovative treatments for people with life-threatening diseases in China." “ Since its establishment at the end of 2017, we are proud to have achieved great results in just a few years. Fu Wei, Chairman of Yunding Xinyao and Chief Executive Officer of Kangqiao Capital, said, "The addition of strong investors not only demonstrates the company's outstanding early results, but also reflects investors' confidence in Yunding Xinyao's growth as a leading innovative pharmaceutical platform company in the region." "Yunding Xinyao is hatched by Kangqiao Capital Investment. "We are excited to work with these outstanding investors in the world's leading biopharmaceutical institutions and look forward to working with them during the exciting and important growth period of Yunding Shinyao," said He Ying, President and Chief Financial Officer of Yunding Xinyao. "Yunding Xinyao has a world-class clinical registration team and an integrated business platform to create a global innovation biopharmaceutical company focused on innovative pharmaceutical research and development and commercialization," said Irene Hong, a partner at Easy Capital, an investment banking consultant on the deal. We are very pleased to be working with a world-class biotechnology company like Yunding Xinyao, and the addition of a number of international first-line investment institutions will help the company accelerate the clinical progress and commercialization of its product pipeline, bringing early benefits to patients in the Asia Pacific region in the four major disease areas. Dr. Zhang Wei, Managing Director of Yikai Capital, said, "The license in model of companies to obtain good products on a global scale is premised on clinical ability to match the world's top pharmaceutical companies. But on the whole, top clinical talent is scarce at home. Yunding Xinyao has a very experienced clinical medical team in the four major disease areas it covers, which is one of the important reasons why it is trusted by its global partners to get the best products in the world and to be able to effectively land in the domestic market. Yunding Xinyao is sought after by many investors in the Asia-Pacific region, and this round of financing is also one of the largest-ever tier-one market transactions in the asia-Pacific biotechnology sector, and is a milestone. We are very bullish on the significant increase in the value of Yunding's new yao financing. Founded 2000, Yikai Capital is China's leading new economic investment bank focused on the three major industries of health, consumption and TMT. Headquartered in Beijing, the company has branches in Shanghai, Los Angeles and San Francisco and holds u.S. securities licenses. In the three years from 2017 to 2019, Yikai Capital has participated in financing and mergers and acquisitions totalling more than 100 billion yuan. Outside the investment banking business, Yikai Capital has been in the asset management business since 2014 and is currently managing a renminbi fund and a US dollar fund. In the healthcare industry, Yikai Capital has the largest, most professional, industry chain covering the most complete investment banking team and has formed a strong market leadership position, has been China for three consecutive years has the largest health industry transaction records of the new economic investment bank. (Arterial mesh)